NEJM February 19 2026 An Antibody–Oligonucleotide Conjugate for Myotonic Dystrophy Type 1
Impossibile aggiungere al carrello
Rimozione dalla Lista desideri non riuscita.
Non è stato possibile aggiungere il titolo alla Libreria
Non è stato possibile seguire il Podcast
Esecuzione del comando Non seguire più non riuscita
NEJM February 19 2026 An Antibody–Oligonucleotide Conjugate for Myotonic Dystrophy Type 1
-
Letto da:
-
Di:
A proposito di questo titolo
This study investigates a novel medical treatment called del-desiran, an innovative therapy designed to combat myotonic dystrophy type 1 by targeting the underlying genetic cause of the disease. By utilizing a specialized antibody-oligonucleotide conjugate, researchers successfully delivered a corrective molecular message directly to muscle cells to reduce the production of toxic messenger RNA. The clinical trial demonstrated that this approach could effectively lower harmful DMPK levels and improve the accuracy of genetic processing, known as alternative splicing. While the results showed promise in repairing cellular function, the study also meticulously tracked safety and side effects to determine the viability of this treatment for patients with this progressive neuromuscular condition.